A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma
Davendra Sohal(University of Cincinnati), Weijing Sun(Huazhong Agricultural University), Antonia R. Sepulveda(University of Pennsylvania), Ursina Teitelbaum(University of Pennsylvania), Mary Carberry(University of Pennsylvania), Paul Wissel(University of Pennsylvania), Takeshi Uehara(Shinshu University), Mona Jacobs-Small(University of Pennsylvania), Bruce J. Giantonio(Massachusetts General Hospital), Nevena Damjanov(University of Pennsylvania), Kristine Mykulowycz(University of Pennsylvania), Peter J. O’Dwyer(University of Pennsylvania)
Cited by 89
Related Papers
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
|The Lancet Oncology|2012|541